


## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1930480/publications.pdf Version: 2024-02-01



FENC YE

#	Article	IF	CITATIONS
1	The Influence of Hormone Therapy on secondary diabetes mellitus in Breast Cancer: A Meta-analysis. Clinical Breast Cancer, 2022, 22, e48-e58.	1.1	12
2	Increased number and function of endothelial progenitor cells in breast cancer patients and the linear correlation with VEGF level. Neoplasma, 2022, 69, 242-250.	0.7	0
3	Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials. BMC Cancer, 2022, 22, 261.	1.1	2
4	Peripheral blood lymphocytes subtypes as new predictors for neoadjuvant therapy efficacy in breast cancer. Cancer Medicine, 2022, 11, 2923-2933.	1.3	2
5	N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. Nature Communications, 2022, 13, 2672.	5.8	80
6	Predictive Nomogram of Subsequent Liver Metastasis After Mastectomy or Breast-Conserving Surgery in Patients With Nonmetastatic Breast Cancer. Cancer Control, 2021, 28, 107327482199741.	0.7	3
7	Identification and Validation of Immune-Related Methylation Clusters for Predicting Immune Activity and Prognosis in Breast Cancer. Frontiers in Immunology, 2021, 12, 704557.	2.2	1
8	A Novel Platelet-Related Gene Signature for Predicting the Prognosis of Triple-Negative Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 795600.	1.8	17
9	Survival benefit of platinum-based regimen in early stage triple negative breast cancer: A meta-analysis of randomized controlled trials. Npj Breast Cancer, 2021, 7, 157.	2.3	10
10	Intraoperative ipsilateral subclavian port catheter implantation in resectable breast cancer patients: A novel, safe, and convenient clinical practice. Cancer Medicine, 2020, 9, 8970-8978.	1.3	0
11	The role of surgical intervention for isolated breast cancer liver metastasis: Results of caseâ€control study with comparison to medical treatment. Cancer Medicine, 2020, 9, 4656-4666.	1.3	6
12	Breastâ€conserving therapy shows better prognosis in mucinous breast carcinoma compared with mastectomy: A SEER populationâ€based study. Cancer Medicine, 2020, 9, 5381-5391.	1.3	8
13	Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies. Breast, 2020, 51, 11-20.	0.9	16
14	circGNB1 Facilitates Triple-Negative Breast Cancer Progression by Regulating miR-141-5p-IGF1R Axis. Frontiers in Genetics, 2020, 11, 193.	1.1	41
15	Breast-Conserving Therapy Versus Mastectomy in Young Breast Cancer Patients Concerning Molecular Subtypes: A SEER Population-Based Study. Cancer Control, 2020, 27, 107327482097666.	0.7	11
16	Hepatitis B virus infection specially increases risk of liver metastasis in breast cancer patients: a propensity-matched analysis. Translational Cancer Research, 2020, 9, 1506-1517.	0.4	6
17	Metformin mediates induction of miRâ€708 to inhibit selfâ€renewal and chemoresistance of breast cancer stem cells through targeting CD47. Journal of Cellular and Molecular Medicine, 2019, 23, 5994-6004.	1.6	52
18	Nomogram to Predict Internal Mammary Lymph Nodes Metastasis in Patients With Breast Cancer. Frontiers in Oncology, 2019, 9, 1193.	1.3	5

Feng Ye

#	Article	IF	CITATIONS
19	miRâ€200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer. Journal of Cellular and Molecular Medicine, 2019, 23, 8114-8127.	1.6	28
20	circFBXW7 Inhibits Malignant Progression by Sponging miR-197-3p and Encoding a 185-aa Protein in Triple-Negative Breast Cancer. Molecular Therapy - Nucleic Acids, 2019, 18, 88-98.	2.3	167
21	Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling. Current Cancer Drug Targets, 2018, 18, 592-599.	0.8	27
22	Development and validation of a nomogram for predicting survival on the base of modified lymph node ratio in breast cancer patients. Breast, 2017, 33, 14-22.	0.9	31
23	The effect of preoperative serum triglycerides and high-density lipoprotein-cholesterol levels on the prognosis of breast cancer. Breast, 2017, 32, 1-6.	0.9	74
24	Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast. Cancer Medicine, 2017, 6, 2489-2496.	1.3	2
25	High Residual Tumor Rate for Early Breast Cancer Patients Receiving Vacuum-assisted Breast Biopsy. Journal of Cancer, 2017, 8, 490-496.	1.2	13
26	High expressions of LDHA and AMPK as prognostic biomarkers for breast cancer. Breast, 2016, 30, 39-46.	0.9	102
27	The miR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer. Scientific Reports, 2016, 6, 21735.	1.6	109
28	The tumor-to-breast volume ratio (TBR) predicts cancer-specific survival in breast cancer patients who underwent modified radical mastectomy. Tumor Biology, 2016, 37, 7493-7500.	0.8	5
29	Diagnostic and prognostic value of serum MACC1 in breast cancer patients. Oncotarget, 2016, 7, 84408-84415.	0.8	21
30	Development and validation of a prognostic nomogram based on the log odds of positive lymph nodes (LODDS) for breast cancer. Oncotarget, 2016, 7, 21046-21053.	0.8	44
31	mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK. Oncotarget, 2016, 7, 35188-35198.	0.8	55
32	The preoperative plasma fibrinogen level is an independent prognostic factor for overall survival of breast cancer patients who underwent surgical treatment. Breast, 2015, 24, 745-750.	0.9	46
33	LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/β-Catenin Signaling. Stem Cells, 2015, 33, 2913-2924.	1.4	135
34	miR-26a suppresses tumour proliferation and metastasis by targeting metadherin in triple negative breast cancer. Cancer Letters, 2015, 357, 384-392.	3.2	85
35	miR-22 as a prognostic factor targets glucose transporter protein type 1 in breast cancer. Cancer Letters, 2015, 356, 410-417.	3.2	81
36	The Practicability of a Novel Prognostic Index (PI) Model and Comparison with Nottingham Prognostic Index (NPI) in Stage l–III Breast Cancer Patients Undergoing Surgical Treatment. PLoS ONE, 2015, 10, e0143537.	1.1	9

Feng Ye

#	Article	IF	CITATIONS
37	miR-200c inhibits breast cancer proliferation by targeting KRAS. Oncotarget, 2015, 6, 34968-34978.	0.8	72
38	BikDDA, a Mutant of Bik with Longer Half-Life Expression Protein, Can Be a Novel Therapeutic Gene for Triple-Negative Breast Cancer. PLoS ONE, 2014, 9, e92172.	1.1	5
39	miR-185 Suppresses Tumor Proliferation by Directly Targeting E2F6 and DNMT1 and Indirectly Upregulating BRCA1 in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 2014, 13, 3185-3197.	1.9	93
40	Diallyl Disulfide Suppresses SRC/Ras/ERK Signaling-Mediated Proliferation and Metastasis in Human Breast Cancer by Up-Regulating miR-34a. PLoS ONE, 2014, 9, e112720.	1.1	67